Sol-Gel Technologies (SLGL) Registration Filing summary

Company overview and business model

• Focuses on innovative dermatology solutions, with two FDA-approved topical drugs for acne and rosacea and a pipeline targeting orphan and rare skin diseases.

• Recent strategic transactions include selling U.S. rights for key products and entering licensing and commercialization agreements in Canada, China, Europe, South Africa, and South Korea.

• Incorporated in Israel, with principal offices in Ness Ziona and shares traded on Nasdaq under the symbol SLGL.

Financial performance and metrics

• As of December 31, 2024, total shareholders' equity was $28.85 million and total capitalization was $35.85 million.

• Aggregate market value of outstanding equity held by non-affiliates was approximately $9.42 million as of April 25, 2025.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D for product candidates and commercialization efforts.